Literature DB >> 8423889

Increase of Parkinson disability after fluoxetine medication.

E N Steur1.   

Abstract

Depression is a major clinical feature of Parkinson's disease. We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine. The possibility of a clinically relevant dopamine-antagonistic capacity of fluoxetine in Parkinson's disease patients must be considered.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8423889     DOI： 10.1212/wnl.43.1_part_1.211

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  21 in total

1.  Depression in Parkinson's Disease.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

2.  Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa.

Authors:  D A M C van de Vijver; R A C Roos; P A F Jansen; A J Porsius; A de Boer
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

Review 3.  Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide.

Authors:  R J Goldberg
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

Review 4.  Depression in Parkinson's disease. Pharmacological characteristics and treatment.

Authors:  T Tom; J L Cummings
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

Review 5.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

Review 6.  Parkinson's disease.

Authors:  C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-06       Impact factor: 10.154

7.  Influence of repeated levodopa administration on rabbit striatal serotonin metabolism, and comparison between striatal and CSF alterations.

Authors:  D A Loeffler; P A LeWitt; P L Juneau; D M Camp; A J DeMaggio; M K Havaich; P E Milbury; W R Matson
Journal:  Neurochem Res       Date:  1998-12       Impact factor: 3.996

Review 8.  Methods of managing levodopa-induced dyskinesias.

Authors:  L T Giron; W C Koller
Journal:  Drug Saf       Date:  1996-06       Impact factor: 5.606

Review 9.  Parkinson's disease and anxiety.

Authors:  K Walsh; G Bennett
Journal:  Postgrad Med J       Date:  2001-02       Impact factor: 2.401

Review 10.  Therapeutic potential of fluoxetine in neurological disorders.

Authors:  Jop P Mostert; Marcus W Koch; Marco Heerings; Dorothea J Heersema; Jacques De Keyser
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.